Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Pediatric Kawasaki Disease
NCT02980263Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of canakinumab in Kawasaki disease (KD), sponsored by Novartis. Planned start Nov 2016; status: withdrawn.
02
Drugs
canakinumab
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on NCT02980263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980263.